Free Trial

Moleculin Biotech (MBRX) Competitors

Moleculin Biotech logo
$0.39 +0.05 (+14.35%)
Closing price 04:00 PM Eastern
Extended Trading
$0.41 +0.02 (+6.22%)
As of 06:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MBRX vs. LPCN, CING, MTEX, GELS, CARM, MRKR, CTXR, RVPH, PMN, and GOVX

Should you be buying Moleculin Biotech stock or one of its competitors? The main competitors of Moleculin Biotech include Lipocine (LPCN), Cingulate (CING), Mannatech (MTEX), Gelteq (GELS), Carisma Therapeutics (CARM), Marker Therapeutics (MRKR), Citius Pharmaceuticals (CTXR), Reviva Pharmaceuticals (RVPH), Promis Neurosciences (PMN), and GeoVax Labs (GOVX). These companies are all part of the "pharmaceutical products" industry.

Moleculin Biotech vs. Its Competitors

Lipocine (NASDAQ:LPCN) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

Lipocine's return on equity of -26.68% beat Moleculin Biotech's return on equity.

Company Net Margins Return on Equity Return on Assets
LipocineN/A -26.68% -24.77%
Moleculin Biotech N/A -278.80%-100.11%

Lipocine has higher revenue and earnings than Moleculin Biotech.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lipocine$11.20M1.49$10K-$1.02-3.05
Moleculin BiotechN/AN/A-$21.76MN/AN/A

Lipocine has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500. Comparatively, Moleculin Biotech has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500.

Lipocine currently has a consensus target price of $9.00, suggesting a potential upside of 189.39%. Moleculin Biotech has a consensus target price of $4.00, suggesting a potential upside of 928.81%. Given Moleculin Biotech's higher probable upside, analysts plainly believe Moleculin Biotech is more favorable than Lipocine.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lipocine
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Moleculin Biotech
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Lipocine and Lipocine both had 1 articles in the media. Moleculin Biotech's average media sentiment score of 1.11 beat Lipocine's score of 0.00 indicating that Moleculin Biotech is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lipocine
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Moleculin Biotech
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

9.1% of Lipocine shares are held by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are held by institutional investors. 6.4% of Lipocine shares are held by company insiders. Comparatively, 1.9% of Moleculin Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Lipocine beats Moleculin Biotech on 5 of the 9 factors compared between the two stocks.

Get Moleculin Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MBRX vs. The Competition

MetricMoleculin BiotechMED IndustryMedical SectorNASDAQ Exchange
Market Cap$5.49M$2.86B$5.45B$8.93B
Dividend YieldN/A2.44%5.22%4.01%
P/E RatioN/A20.4427.2420.06
Price / SalesN/A283.79426.37117.54
Price / CashN/A41.7026.2128.59
Price / Book0.227.397.925.56
Net Income-$21.76M-$55.04M$3.17B$248.56M
7 Day Performance28.78%3.43%4.40%7.56%
1 Month Performance-41.97%0.16%2.64%8.54%
1 Year Performance-88.86%4.49%35.04%21.81%

Moleculin Biotech Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MBRX
Moleculin Biotech
3.1483 of 5 stars
$0.39
+14.4%
$4.00
+928.8%
-90.0%$5.49MN/A0.0020Positive News
High Trading Volume
LPCN
Lipocine
1.5717 of 5 stars
$3.16
-4.0%
$9.00
+184.8%
-55.1%$17.60M$11.20M-3.1010
CING
Cingulate
2.7003 of 5 stars
$4.07
+0.5%
$26.00
+538.8%
+1,174.1%$17.19MN/A-0.4820Gap Up
MTEX
Mannatech
0.2741 of 5 stars
$9.35
+3.9%
N/A+25.8%$17.11M$117.87M-93.50250High Trading Volume
GELS
Gelteq
N/A$1.73
-4.4%
N/AN/A$17.08M$100K0.00N/AGap Down
CARM
Carisma Therapeutics
2.3672 of 5 stars
$0.39
-2.2%
$1.93
+391.6%
-64.7%$16.74M$19.63M-0.2520
MRKR
Marker Therapeutics
3.2093 of 5 stars
$1.53
+4.8%
$13.17
+760.6%
-68.3%$16.52M$6.59M-1.1560Positive News
Gap Up
CTXR
Citius Pharmaceuticals
2.3996 of 5 stars
$1.59
+3.9%
$53.00
+3,233.3%
-83.4%$16.27MN/A0.0020High Trading Volume
RVPH
Reviva Pharmaceuticals
2.2537 of 5 stars
$0.38
+12.9%
$9.00
+2,261.6%
-68.5%$16.20MN/A-0.485Gap Up
High Trading Volume
PMN
Promis Neurosciences
3.3859 of 5 stars
$0.48
+0.7%
$4.50
+830.1%
-74.1%$15.70MN/A-9.685Gap Up
GOVX
GeoVax Labs
3.3284 of 5 stars
$0.87
-9.8%
$11.10
+1,182.2%
-82.9%$15.29M$3.95M-0.2410Analyst Downgrade

Related Companies and Tools


This page (NASDAQ:MBRX) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners